Trade Name: Trulicity

Following information is meant for : Wholesalers, Suppliers, Exporters, Doctors, CROs, Comparator Supplies, Hospitals, MOH Tender Supplies, Generic, Brand, Cooperate Sourcing, India, Institutional Buyers.

Manufacturer: Eli Lilly and Company

Presentation: INJECTION, SOLUTION, HUMAN PRESCRIPTION DRUG

Strength: 0.75 mg/.5mL

Storage and handling

DULAGLUTIDE GLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [CS],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]

Disclaimer:
  1. These products are NOT FOR SALE in US territories. We offer them for Exports outside of US Territories to Trade Professionals or patients with a valid prescription.
  2. Trademark shown are property of their respective owners and GNH India does not lay any claim on them.
  3. Read more
  • No data
  • No data
  • WARNING: RISK OF THYROID C-CELL TUMORS
  • See full prescribing information for complete boxed warning.
  • Dulaglutide causes thyroid C-cell tumors in rats. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined (, ).
  • TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (, ).
  • TRULICITY is indicatedn
  • TRULICITY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated:n
  • Limitations of Use:
  • No data
  • Administer once weekly at any time of day ().n
  • Inject subcutaneously in the abdomen, thigh, or upper arm ().n
  • Initiate at 0.75 mg subcutaneously once weekly. Dose can be increased to 1.5 mg once weekly for additional glycemic control ().n
  • If a dose is missed, administer the missed dose as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose ().n
  • No data
  • Injection: 0.75 mg/0.5 mL solution in a single-dose pen ()n
  • Injection: 1.5 mg/0.5 mL solution in a single-dose pen ()n
  • No data
  • TRULICITY is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (, ).n
  • TRULICITY is contraindicated in patients with a prior serious hypersensitivity reaction to TRULICITY or any of the product components (, ).n
  • No data
  • Thyroid C-cell Tumors:
  • Pancreatitis:
  • Hypoglycemia:
  • Hypersensitivity Reactions:
  • Acute Kidney Injury:
  • Severe Gastrointestinal Disease:
  • Diabetic Retinopathy Complications:n- outcomes
  • The following serious reactions are described below or elsewhere in the prescribing information:n
  • The most common adverse reactions, reported in u22655% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite ().n
  • To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • TRULICITY slows gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with TRULICITY. Drug levels of oral medications with a narrow therapeutic index should be adequately monitored when concomitantly administered with TRULICITY. In clinical pharmacology studies, TRULICITY did not affect the absorption of the tested, orally administered medications to a clinically relevant degree .n
  • TRULICITY slows gastric emptying and may impact absorption of concomitantly administered oral medications (, ).n
  • No data
  • Pregnancy: TRULICITY should be used during pregnancy only if the potential benefit justifies the potential risk to fetus ().n
  • Renal Impairment: No dosage adjustment recommended. Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions (, ).n
  • Overdoses have been reported in clinical studies. Effects associated with these overdoses were primarily mild or moderate gastrointestinal events (e.g., nausea, vomiting) and non-severe hypoglycemia. In the event of overdose, appropriate supportive care (including frequent plasma glucose monitoring) should be initiated according to the patient's clinical signs and symptoms.n
  • TRULICITY contains dulaglutide, a human GLP-1 receptor agonist. The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37). Structural modifications were introduced in the GLP-1 part of the molecule responsible for interaction with the enzyme dipeptidyl-peptidase-IV (DPP-4). Additional modifications were made in an area with a potential T-cell epitope and in the areas of the IgG4 Fc part of the molecule responsible for binding the high-affinity Fc receptors and half-antibody formation. The overall molecular weight of dulaglutide is approximately 63u00a0kilodaltons.n
  • TRULICITY is a clear, colorless, sterile solution. Each 0.5u00a0mL of TRULICITY solution contains 0.75 mg or 1.5u00a0mg of dulaglutide. Each single-dose pen contains 0.5u00a0mL of solution and the following excipients: citric acid anhydrous (0.07 mg), mannitol (23.2 mg), polysorbate 80 (0.10 mg), trisodium citrate dihydrate (1.37 mg), in water for injection.n
  • No data
  • No data
  • No data
  • No data
  • See n
  • Eli Lilly and Company, Indianapolis, IN 46285, USAUS License Number 1891n
  • TRU-0011-USPI-20200221n
  • No data
  • No data
  • No data
  • NDC 0002-1433-80n
  • 4 Single-Dose Pensn
  • Each pen delivers a 0.75 mg dose.n
  • Use one pen every week.n
  • trulilcityn
  • (dulaglutide) injectionn
  • 0.75 mg/0.5 mLn
  • once weeklyn
  • Rx onlyn
  • For subcutaneous use onlyn
  • Single-Dose Onlyn
  • Dispense the accompanying Medication Guide to each patient.n
  • www.trulicity.comn
  • Lillyn
  • NDC 0002-1434-80n
  • 4 Single-Dose Pensn
  • Each pen delivers a 1.5 mg dose.n
  • Use one pen every week.n
  • trulicityn
  • (dulaglutide) injectionn
  • 1.5 mg/0.5 mLn
  • once weeklyn
  • Rx onlyn
  • For subcutaneous use onlyn
  • Single-Dose Only
  • Dispense the accompanying Medication Guide to each patient.n
  • www.trulicity.comn
  • Lillyttttttn

Request for Quote

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler, Supplier, Exporters from India of Dulaglutide (Trulicity) which is also known as Trulicity and Manufactured by Eli Lilly and Company. It is available in strength of 0.75 mg/.5mL.

Dulaglutide (Trulicity) is supplied for Tenders, Emergency imports, Un - licensed, Specials, Orphan drug, Name patient line, RLD supplies, Reference listed drugs, Comparator Drug, Bio-Similar, Innovator samples, For Clinical trials. Click to know price.

Browse Our Services And Processes

Name Patient Supply

Name Patient Supply

Validated Cold Chain Shipment

Validated Cold Chain Shipment

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

Our Process - The Gnh Way

Our Process - The Gnh Way

Other Pharmaceutical Products

Triamcinolone Acetonide (Triamcinolone Acetonide)

Triamcinolone Acetonide (Triamcinolone Acetonide)

Actylise

Actylise

Abraxane-Paclitaxel

Abraxane-Paclitaxel

Liposomal Amphotericin - B for Injection IP (AmBisome)

Liposomal Amphotericin - B for Injection IP (AmBisome)

Edatate Calcium Disodium Injection USP 200mg/ml (Cal-Rsodate)

Edatate Calcium Disodium Injection USP 200mg/ml (Cal-Rsodate)

Melphalan Injection IP 50mg (Alkacel)

Melphalan Injection IP 50mg (Alkacel)

Are you an existing customer or a vendor of GNH India? Log in here to